Plain-English translation of NCT06580106 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand why some patients respond well to azacitidine and venetoclax—two medications commonly used to treat newly diagnosed acute myeloid leukemia—while others experience more side effects or don't respond as well. This study collects cheek swabs and blood samples from patients receiving this treatment to see if certain genes affect how the medication works in their body and how they tolerate it.
Doctors know that patients react differently to the same medications, and some people have more trouble with side effects than others. This research aims to discover whether genetic differences can predict which patients will do well with this treatment and which ones might need dose adjustments or a different approach.
You likely qualify if…
You likely don't qualify if…
You will provide a cheek swab (using a brush inside your mouth) for genetic testing, and your doctor will collect blood samples to measure medication levels while you receive your standard cancer treatment. The study team will also track how you respond to treatment, any side effects you experience, and your overall health for up to three years. All of this happens alongside your regular medical care—there are no additional medications or procedures just for the study.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States
Sponsor
Wake Forest University Health Sciences
Collaborators
Atrium Health Levine Cancer Institute, Swim Across America
Enrollment target
~50 participants
Started
April 2025
Primary completion
July 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Courtney Schepel
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.